An interventional study of pulmonary vein isolation and roof line ablation and GP ablation in Atrial Fibrillation, sponsored by Institute for Clinical and Experimental Medicine. Not yet recruiting at 1 site in Czechia. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Institute for Clinical and Experimental Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Atrial Fibrillation with a site in Czechia — 39 open to participants now, 50 under way, 6 of them phase 3. Atrial Fibrillation · Czechia.
Among the 184 studies in Atrial Fibrillation with a site in Czechia, this one is the 65th largest by planned enrollment of the 153 interventional ones that give a count, is one of 2 that started in 2027, is one of 96 with no phase, reaches primary completion later than 39 of the 49 other live ones, and was the 175th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.
Browse Atrial Fibrillation studies →39 of the 184 studies in Atrial Fibrillation with a site in Czechia are open now. Recruiting first, the newest first:
Mitera Hospital · Sites in Czechia, Croatia, Greece and 5 more countries
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18–80
Motol and Homolka University Hospital · Sites in Czechia
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Czechia, United States, Australia and 3 more countries
Ages 18+
Pulse Biosciences, Inc. · Sites in Czechia
Ages 18–85
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 38 · Phase 4 10
First in 1999; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 153 interventional studies, 540 across the 29 observational. Of the 125 that completed or were terminated, 62 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 184 have an industry lead sponsor. The 10 most frequent:
Institute for Clinical and Experimental Medicine is the lead sponsor of 61 studies on the registry; 21 are open to participants now.
Institute for Clinical and Experimental Medicine has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
13 of the studies in Atrial Fibrillation with a site in Czechia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07210151LUMA Vision Ltd.Anatomical Navigation for Guided Electrophysiology in AFL and AFib | 2026-12-16 |
| NCT06529978CoreMap Inc.Endocardial Mapping With the CoreMap EP Mapping System | 2026-12-31 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT06510556Boston Scientific CorporationFeasibility Study of the FARAFLEX Mapping and PFA System | 2027-02-15 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Atrial Fibrillation with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.
The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.
The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.
The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:
Patients who are willing and capable of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field
Procedure: pulmonary vein isolation and roof line ablation · Procedure: GP ablation
Pulmonary vein isolation and roof line ablation using pulsed electric field energy
Procedure: pulmonary vein isolation and roof line ablation
isolation of pulmonary veins and roof line ablation using pulsed electric energy
ablation of GP using radiofrequency energy
Freedom from recurrent AF/AT >30 s during the first 12 months
The primary outcome of the study is freedom from recurrent AF/AT \>30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs.
Time frame: From the ablation procedure through the 12-month follow-up.
Quality of life
This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life).
Time frame: Baseline and at the 12-month visit.
Periprocedural complications, MACE
periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up
Time frame: From the ablation procedure through the 12-month follow-up.
Acute vagal denervation assessed by ECVS
ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded.
Time frame: Periprocedural
Long-term cardiac vagal denervation
Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection.
Time frame: Baseline and at the 12-month visit.
Vagal atrial induction test (VAFIT)
This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS.
Time frame: Periprocedural
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Apr 2028, 12 months later.
Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 12 months is below that.
Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute for Clinical and Experimental Medicine